Zobrazeno 1 - 10
of 198
pro vyhledávání: '"anthracycline-induced cardiomyopathy"'
Autor:
Hirotaka Oda, Yuka Hayashi, Norihito Oyanagi, Komei Tanaka, Kazuyuki Ozaki, Asami Kashiwa, Yukio Hosaka, Keiichi Tsuchida, Kazuyoshi Takahashi
Publikováno v:
BMC Cardiovascular Disorders, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background The overall mortality and morbidity benefit in patients with heart failure with a reduced ejection fraction is greatest with a treatment combination of sacubitril/valsartan, beta-blockers, mineralocorticoid-receptor antagonists, a
Externí odkaz:
https://doaj.org/article/a71cdddb4a704404aaab66d964d5af74
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Open Veterinary Journal, Vol 11, Iss 1, Pp 6-10 (2021)
Background: Canine lymphoma is one of the most frequently occurring malignant neoplasms in dogs. Anthracycline-based chemotherapy for the treatment of canine lymphoma is very effective; however, there is not enough evidence for the development of car
Externí odkaz:
https://doaj.org/article/fcac03d2926d48239ed565852ca644c7
Autor:
Timothy N. McOwan, Lauren A. Craig, Anne Tripdayonis, Kathy Karavendzas, Michael M. Cheung, Enzo R. Porrello, Rachel Conyers, David A. Elliott
Publikováno v:
Cardio-Oncology, Vol 6, Iss 1, Pp 1-6 (2020)
Abstract Background Anthracyclines are a mainstay of chemotherapy. However, a relatively frequent adverse outcome of anthracycline treatment is cardiomyopathy. Multiple genetic studies have begun to dissect the complex genetics underlying cardiac sen
Externí odkaz:
https://doaj.org/article/00a1c81a173c4ade91cf57973bb5ce84
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Онкогематология, Vol 12, Iss 3, Pp 25-30 (2017)
Introduction. The anthracycline antibiotics cause clinically significant manifestations of cardiotoxicity (СТ) – myocardial injuries, reducing both quality and life expectancy of the oncological patients.The purpose of the study was to evaluate t
Externí odkaz:
https://doaj.org/article/e1c098ddacbb4429b9c7a7cbbe000aa2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Robert Sinclair, Yitian Zeng, Gentaro Ikeda, Ji Hye Jung, Christine Wahlquist, Utkan Demirci, Yunshin Jung, Nathan Bayardo, Adrian P. Gee, Connor O'Brien, Zewen Jiang, Katrin J. Svensson, Elizabeth S. Egan, Evgeniya Vaskova, Michelle R. Santoso, Phillip C. Yang, Ronald M. Witteles, Mark Mercola, Mehmet Ozgun Ozen, Liye Shi
Publikováno v:
JACC: CardioOncology
Background Anthracycline-induced cardiomyopathy (AIC) is a significant source of morbidity and mortality in cancer survivors. The role of mesenchymal stem cells (MSCs) in treating AIC was evaluated in the SENECA trial, a Phase 1 National Heart, Lung,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c25d014101ed00cc5bea7576b26705
https://doi.org/10.1016/j.jaccao.2021.05.006
https://doi.org/10.1016/j.jaccao.2021.05.006
Publikováno v:
Open Veterinary Journal, Vol 11, Iss 1, Pp 6-10 (2021)
Open Veterinary Journal
Open Veterinary Journal
Background: Canine lymphoma is one of the most frequently occurring malignant neoplasms in dogs. Anthracycline-based chemotherapy for the treatment of canine lymphoma is very effective; however, there is not enough evidence for the development of car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcc8a601542805b1deb5210b6194e1ba
https://doi.org/10.4314/ovj.v11i1.2
https://doi.org/10.4314/ovj.v11i1.2
Autor:
Kaskinen, Anu K., Helle, Emmi, Pihkala, Jaana, Jahnukainen, Timo, Kanerva, Jukka, Mäyränpää, Mikko I., Lemström, Karl, Mattila, Ilkka, Ojala, Tiina
Publikováno v:
JACC Case Reports
A 9-year-old boy developed progressive anthracycline-induced cardiomyopathy three months after completion of chemotherapy for osteosarcoma. Five months after completion of chemotherapy, at the age of 10 years, heart transplantation was performed. At
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::0fe18a5e654e33c438f63724768cb184
http://europepmc.org/articles/PMC8571779
http://europepmc.org/articles/PMC8571779